How much funding has Vividion Therapeutics raised?

Vividion Therapeutics has raised $368.0M in total funding, most recently a Series C round.

Who are Vividion Therapeutics's investors?

Vividion Therapeutics's investors include Logos Capital, Boxer Capital, Nextech Invest, ARCH Venture Partners, Jerel Davis.

When was Vividion Therapeutics founded?

Vividion Therapeutics was founded in 2016.

Where is Vividion Therapeutics headquartered?

Vividion Therapeutics is headquartered in San Diego, California, United States.

What industry is Vividion Therapeutics in?

Vividion Therapeutics operates in Biotech, Drug Discovery.

How many employees does Vividion Therapeutics have?

Vividion Therapeutics has 201-500 employees.

Vividion Therapeutics

Acquired

Leading the small molecule Revolution

San Diego, United States · Founded 2016 · $368.0M raised

Biotech

Drug Discovery

Headquarters: San Diego, California
Employees: 201–500
Founded: 2016
Business Model: B2B

Website: vividion.com
Total Funding: $368.0M
Last Round: $135.0M Series CFeb 2021
Rounds: 4

About

Vividion Therapeutics is a San Diego-based biopharmaceutical company leveraging proprietary chemoproteomics technology to identify and drug previously undruggable protein targets for devastating cancers and immune disorders. Founded in 2016 as a spin-out of Scripps Research Institute, the company was acquired by Bayer AG in September 2021 for up to $2 billion and continues to operate as an autonomous subsidiary. Vividion has more than 200 employees and maintains active research and development programs.

Summary

Vividion Therapeutics is a Biotech company based in San Diego, United States, founded in 2016. It has raised $368.0M in total across 4 rounds, most recently a $135.0M Series C round in Feb 2021. Investors include Logos Capital, Boxer Capital and Nextech Invest.